{"id":11403681,"date":"2026-07-15T02:50:30","date_gmt":"2026-07-14T23:50:30","guid":{"rendered":"https:\/\/nostylelike.net\/?post_type=product&p=11403681"},"modified":"2026-08-27T14:20:45","modified_gmt":"2026-08-27T11:20:45","slug":"opzelura-15-mg-g-ruxolitinib-cream","status":"publish","type":"product","link":"https:\/\/nostylelike.net\/en\/product\/opzelura-15-mg-g-ruxolitinib-cream\/","title":{"rendered":"Opzelura 15 mg\/g Cream: 7 Safety Checks for Vitiligo"},"content":{"rendered":"

Opzelura 15 mg\/g cream<\/strong> is a prescription topical medicine containing 15 mg of ruxolitinib per gram of cream. Ruxolitinib inhibits Janus kinase 1 and 2 (JAK1\/JAK2). Under the current European authorisation, it is used for non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Treatment should be started and supervised by a doctor experienced in diagnosing and treating vitiligo.<\/p>\n

\"Front<\/p>\n

Important:<\/strong> Opzelura 15 mg\/g cream is not a cosmetic lightening product and it is not a cure-all for every type of white skin patch. A dermatologist should confirm the diagnosis because fungal infection, post-inflammatory colour change and other disorders can resemble vitiligo. Use only the pack, strength and instructions prescribed for the individual patient.<\/p>\n

Opzelura 15 mg\/g cream quick facts<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
Brand<\/th>\nOpzelura 15 mg\/g cream<\/td>\n<\/tr>\n
Active ingredient<\/th>\nRuxolitinib as ruxolitinib phosphate<\/td>\n<\/tr>\n
Medicine class<\/th>\nTopical JAK1\/JAK2 inhibitor<\/td>\n<\/tr>\n
EU-authorised use<\/th>\nNon-segmental vitiligo with facial involvement<\/td>\n<\/tr>\n
Age<\/th>\nAdults and adolescents aged 12 years and older<\/td>\n<\/tr>\n
Usual application<\/th>\nA thin layer twice daily, at least 8 hours apart<\/td>\n<\/tr>\n
Maximum treated area<\/th>\n10% of body surface area<\/td>\n<\/tr>\n
Pack shown<\/th>\nOne 100 g tube<\/td>\n<\/tr>\n
Supply<\/th>\nPrescription only<\/td>\n<\/tr>\n
Storage<\/th>\nBelow 30\u00b0C; use within 6 months after opening<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

What Opzelura 15 mg\/g cream is used for<\/h2>\n

Non-segmental vitiligo is an acquired condition in which functioning pigment-producing cells are lost from areas of skin, creating depigmented patches that are usually distributed on both sides of the body. The authorised European indication specifically includes facial involvement. Opzelura 15 mg\/g cream may be considered when the clinician decides that topical JAK inhibition is appropriate after reviewing the pattern, extent, activity and previous treatment of the disease.<\/p>\n

The current EU product information does not describe every ruxolitinib cream use authorised in other countries. National indications can differ. For this 100 g EU pack, this page follows the current European product information for vitiligo. Do not copy an eczema dose or age limit from a US pack or website without confirmation from the prescribing clinician and the leaflet supplied with the actual medicine.<\/p>\n

How ruxolitinib cream works<\/h2>\n

Signals involving interferon-gamma and the JAK-STAT pathway help maintain immune activity around melanocytes in vitiligo. Ruxolitinib inhibits JAK1 and JAK2, reducing selected signalling pathways involved in that immune response. This may allow repigmentation to develop gradually in treated areas. The response is not immediate, and individual results vary according to the body site, disease duration, adherence and other clinical factors.<\/p>\n

Because the medicine affects immune signalling, it should be used only on the area and for the duration advised by the dermatologist. Applying a thicker layer does not make repigmentation faster and may increase exposure. Treatment success should be assessed with consistent clinical photographs and scheduled medical review rather than day-to-day colour changes.<\/p>\n

How to apply Opzelura correctly<\/h2>\n
    \n
  1. Wash and dry the hands and make sure the treatment area is clean and dry.<\/li>\n
  2. Apply a thin layer to the depigmented areas selected by the prescriber.<\/li>\n
  3. Use it twice daily with at least 8 hours between applications.<\/li>\n
  4. Do not treat more than 10% of total body surface area. Ten handprints of the patient, including the fingers, are approximately 10%.<\/li>\n
  5. Avoid the eyes, lips, mouth and other mucous membranes.<\/li>\n
  6. Wash the hands after application unless the hands themselves are being treated.<\/li>\n
  7. Avoid washing treated skin for approximately 2 hours after application.<\/li>\n
  8. Wait at least 2 hours before applying another topical medicine, sunscreen or moisturiser to the same area unless the dermatologist gives different instructions.<\/li>\n<\/ol>\n

    The recommended monthly limit is no more than two 100 g tubes. Do not cover treated areas with an airtight dressing unless specifically instructed. If a dose is missed, apply the next dose at the usual time; do not apply a double amount to compensate.<\/p>\n

    \"Opzelura<\/p>\n

    How long repigmentation may take<\/h2>\n

    Satisfactory repigmentation may require treatment beyond 24 weeks. Slow improvement does not automatically mean failure, but regular follow-up is important. If less than 25% repigmentation is present in treated areas at week 52, the product information says discontinuation should be considered. The clinician weighs visible change, patient goals, tolerability and the benefit of continuing.<\/p>\n

    Once satisfactory repigmentation has been achieved in an area, treatment there may be stopped. If depigmentation returns after stopping, the clinician may advise restarting treatment on the affected area. Never continue indefinitely without medical review, and do not use someone else’s prescription.<\/p>\n

    Who should not use Opzelura<\/h2>\n

    Do not use Opzelura 15 mg\/g cream if there is hypersensitivity to ruxolitinib or any excipient. It must not be used during pregnancy or breastfeeding. People who could become pregnant should follow the contraception advice in the supplied leaflet and from their clinician. The medicine is not authorised in the EU for children under 12 years for this vitiligo indication.<\/p>\n

    Tell the dermatologist about active skin infection, previous shingles, recurrent infections, skin cancer, unusual moles, immune-system disorders, major kidney disease and all current medicines. Use in end-stage renal disease has not been studied and is not recommended in the product information.<\/p>\n

    Seven essential safety checks<\/h2>\n